Effectiveness of Short Courses of Application of Antiseptic Gel in Initial Inflammation of Peri-Implant Tissue

The subject of the research is the treatment of peri-implant mucositis. The goal is to clinically evaluate the effectiveness of the antiseptic gel “Curasept ADS 350” for initial inflammation of peri-implant tissues. Methodology. The group of subjects included 66 patients (23 men, 43 women) aged from 41 to 64 years (average age 52.17 ± 1.23 years). Their initial peri-implant mucositis was relieved by using the “gum” gel “Curasept ADS 350” (Italy) with 0.5% chlorhexidine bigluconate. To analyze the health status of peri-implant tissues, clinical, radiological, clinical-laboratory and clinical-sociological examination methods were used. Statistical processing of materials was carried out using SAS v9.4 software. Results. After 2–3 weeks of treatment, including day and night applications of the therapeutic antiseptic gel "Curasept ADS 350", individual signs of mucositis remained in only one person (1.52%), who was successfully given a second course of complex therapy, including local antibiotic administration. The depth of the cuff pockets, probably due to swelling, was greatest. After treatment and in the long term, it statistically significantly decreased (p < 0.001). Clinical and social author's methods of examining the expert assessment “TAPATR” and patients' self-assessment of the condition of peri-implant tissues “PARTAT” demonstrated a significant improvement (p < 0.01) in the level of health and its preservation 3 months after treatment (p < 0.02). Conclusion 1. Almost all (pathognomonic and highly specific) signs of inflammation were obvious in the vast majority of those examined (96.97–100%). They had not yet developed pain, which in some patients (4 people, 6.06%) was caused by light pressure or palpation of soft peri-implant tissues. In particular, in this regard, all of them were diagnosed with “initial” peri-implant mucositis. 2. The use of the antiseptic gel “Curasept” demonstrated high efficiency, since after 5 days of taking it, the symptoms of inflammation completely disappeared in the vast majority of those examined (65 people, 98.48%), was partially reduced in another patient (1.52%) and were completely eliminated during a second course of treatment.